All JNK1 reagents are produced in house and quality controlled, including 3 JNK1 Antibody, 30 JNK1 Gene, 1 JNK1 IPKit, 1 JNK1 Lysate, 1 JNK1 Protein, 2 JNK1 qPCR. All JNK1 reagents are ready to use.
Recombinant JNK1 proteins are expressed by Baculovirus-Insect Cells with fusion tags as N-GST.
JNK1antibodies are validated with different applications, which are ELISA, IHC-P, ICC/IF, IF, WB, IP.
JNK1cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each JNK1 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
Mitogen-activated protein kinase 8 (MAPK8), also known as JNK1, is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The protein kinases JNK1 has been found to serve as critical molecular links between obesity, metabolic inflammation, and disorders of glucose homeostasis. It is critically involved in the promotion of diet-induced obesity, metabolic inflammation and beta-cell dysfunction. The selective deficiency of JNK1 in the murine nervous system is sufficient to suppress diet-induced obesity. Genetic analysis indicates that the effects of JNK1 can be separated from effects of JNK1 on obesity. JNK1 is a potential pharmacological target for the development of drugs that might be useful for the treatment of metabolic syndrome, and type 2 diabetes. Furthermore, JNK1 plays a major role in the hypoxic cellular damage. JNK1 protein might be an attractive target for antihypoxic therapy in increasing resistance to many pathological conditions and diseases, leading to the oxygen deficit.